vs
Amphastar Pharmaceuticals, Inc.（AMPH）与Rapid7, Inc.（RPD）财务数据对比。点击上方公司名可切换其他公司
Rapid7, Inc.的季度营收约是Amphastar Pharmaceuticals, Inc.的1.2倍（$217.4M vs $183.1M），Amphastar Pharmaceuticals, Inc.净利率更高（13.3% vs 1.4%，领先11.9%），Rapid7, Inc.同比增速更快（0.5% vs -1.8%），Rapid7, Inc.自由现金流更多（$36.4M vs $24.6M），过去两年Amphastar Pharmaceuticals, Inc.的营收复合增速更高（3.2% vs 3.0%）
安福斯制药是一家上市的美国特种制药企业，公司成立于2004年5月，核心业务为吸入制剂及鼻腔给药产品的研发、生产与销售，聚焦特色医药领域深耕发展。
Rapid7是全球领先的网络安全企业，提供漏洞管理、威胁检测与响应、云安全、安全分析等全系列安全解决方案，服务全球科技、医疗、金融、制造等行业的各类规模企业及公共部门客户，助力客户高效识别、应对和缓解网络安全风险。
AMPH vs RPD — 直观对比
营收规模更大
RPD
是对方的1.2倍
$183.1M
营收增速更快
RPD
高出2.4%
-1.8%
净利率更高
AMPH
高出11.9%
1.4%
自由现金流更多
RPD
多$11.8M
$24.6M
两年增速更快
AMPH
近两年复合增速
3.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $183.1M | $217.4M |
| 净利润 | $24.4M | $3.1M |
| 毛利率 | 46.8% | 68.9% |
| 营业利润率 | 19.4% | 1.0% |
| 净利率 | 13.3% | 1.4% |
| 营收同比 | -1.8% | 0.5% |
| 净利润同比 | -35.7% | 44.1% |
| 每股收益（稀释后） | $0.51 | $0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMPHRPD
| Q4 25 | $183.1M | $217.4M | ||
| Q3 25 | $191.8M | $218.0M | ||
| Q2 25 | $174.4M | $214.2M | ||
| Q1 25 | $170.5M | $210.3M | ||
| Q4 24 | $186.5M | $216.3M | ||
| Q3 24 | $191.2M | $214.7M | ||
| Q2 24 | $182.4M | $208.0M | ||
| Q1 24 | $171.8M | $205.1M |
净利润AMPHRPD
| Q4 25 | $24.4M | $3.1M | ||
| Q3 25 | $17.4M | $9.8M | ||
| Q2 25 | $31.0M | $8.3M | ||
| Q1 25 | $25.3M | $2.1M | ||
| Q4 24 | $38.0M | $2.2M | ||
| Q3 24 | $40.4M | $15.4M | ||
| Q2 24 | $37.9M | $6.5M | ||
| Q1 24 | $43.2M | $1.4M |
毛利率AMPHRPD
| Q4 25 | 46.8% | 68.9% | ||
| Q3 25 | 51.4% | 70.2% | ||
| Q2 25 | 49.6% | 70.6% | ||
| Q1 25 | 50.0% | 71.7% | ||
| Q4 24 | 46.5% | 69.5% | ||
| Q3 24 | 53.3% | 70.6% | ||
| Q2 24 | 52.2% | 70.7% | ||
| Q1 24 | 52.4% | 70.3% |
营业利润率AMPHRPD
| Q4 25 | 19.4% | 1.0% | ||
| Q3 25 | 13.2% | 2.7% | ||
| Q2 25 | 24.2% | 1.6% | ||
| Q1 25 | 21.9% | -0.0% | ||
| Q4 24 | 24.2% | 3.4% | ||
| Q3 24 | 29.8% | 6.0% | ||
| Q2 24 | 30.3% | 2.5% | ||
| Q1 24 | 27.9% | 4.7% |
净利率AMPHRPD
| Q4 25 | 13.3% | 1.4% | ||
| Q3 25 | 9.0% | 4.5% | ||
| Q2 25 | 17.8% | 3.9% | ||
| Q1 25 | 14.8% | 1.0% | ||
| Q4 24 | 20.4% | 1.0% | ||
| Q3 24 | 21.1% | 7.2% | ||
| Q2 24 | 20.8% | 3.1% | ||
| Q1 24 | 25.1% | 0.7% |
每股收益（稀释后）AMPHRPD
| Q4 25 | $0.51 | $0.05 | ||
| Q3 25 | $0.37 | $0.15 | ||
| Q2 25 | $0.64 | $0.13 | ||
| Q1 25 | $0.51 | $0.03 | ||
| Q4 24 | $0.74 | $0.08 | ||
| Q3 24 | $0.78 | $0.21 | ||
| Q2 24 | $0.73 | $0.09 | ||
| Q1 24 | $0.81 | $0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $282.8M | $474.7M |
| 总债务越低越好 | $608.7M | — |
| 股东权益账面价值 | $788.8M | $154.7M |
| 总资产 | $1.6B | $1.7B |
| 负债/权益比越低杠杆越低 | 0.77× | — |
8季度趋势，按日历期对齐
现金及短期投资AMPHRPD
| Q4 25 | $282.8M | $474.7M | ||
| Q3 25 | $276.2M | $407.1M | ||
| Q2 25 | $231.8M | $511.7M | ||
| Q1 25 | $236.9M | $493.5M | ||
| Q4 24 | $221.6M | $521.7M | ||
| Q3 24 | $250.5M | $443.7M | ||
| Q2 24 | $217.8M | $442.6M | ||
| Q1 24 | $289.6M | $411.7M |
总债务AMPHRPD
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — | ||
| Q1 24 | $594.0M | — |
股东权益AMPHRPD
| Q4 25 | $788.8M | $154.7M | ||
| Q3 25 | $776.7M | $127.2M | ||
| Q2 25 | $757.5M | $90.4M | ||
| Q1 25 | $751.3M | $52.7M | ||
| Q4 24 | $732.3M | $17.7M | ||
| Q3 24 | $727.7M | $-5.1M | ||
| Q2 24 | $713.3M | $-52.6M | ||
| Q1 24 | $672.4M | $-86.4M |
总资产AMPHRPD
| Q4 25 | $1.6B | $1.7B | ||
| Q3 25 | $1.7B | $1.7B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.6B | ||
| Q2 24 | $1.5B | $1.5B | ||
| Q1 24 | $1.6B | $1.5B |
负债/权益比AMPHRPD
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — | ||
| Q1 24 | 0.88× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $32.9M | $37.6M |
| 自由现金流经营现金流 - 资本支出 | $24.6M | $36.4M |
| 自由现金流率自由现金流/营收 | 13.4% | 16.8% |
| 资本支出强度资本支出/营收 | 4.5% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.35× | 12.01× |
| 过去12个月自由现金流最近4个季度 | $121.2M | $146.2M |
8季度趋势，按日历期对齐
经营现金流AMPHRPD
| Q4 25 | $32.9M | $37.6M | ||
| Q3 25 | $52.6M | $39.0M | ||
| Q2 25 | $35.6M | $47.5M | ||
| Q1 25 | $35.1M | $29.8M | ||
| Q4 24 | $29.0M | $63.8M | ||
| Q3 24 | $60.0M | $44.0M | ||
| Q2 24 | $69.1M | $32.9M | ||
| Q1 24 | $55.3M | $31.1M |
自由现金流AMPHRPD
| Q4 25 | $24.6M | $36.4M | ||
| Q3 25 | $47.2M | $34.8M | ||
| Q2 25 | $25.0M | $46.6M | ||
| Q1 25 | $24.4M | $28.4M | ||
| Q4 24 | $16.6M | $62.6M | ||
| Q3 24 | $46.2M | $42.6M | ||
| Q2 24 | $63.1M | $32.6M | ||
| Q1 24 | $46.5M | $30.4M |
自由现金流率AMPHRPD
| Q4 25 | 13.4% | 16.8% | ||
| Q3 25 | 24.6% | 16.0% | ||
| Q2 25 | 14.3% | 21.8% | ||
| Q1 25 | 14.3% | 13.5% | ||
| Q4 24 | 8.9% | 28.9% | ||
| Q3 24 | 24.1% | 19.9% | ||
| Q2 24 | 34.6% | 15.7% | ||
| Q1 24 | 27.1% | 14.8% |
资本支出强度AMPHRPD
| Q4 25 | 4.5% | 0.5% | ||
| Q3 25 | 2.8% | 1.9% | ||
| Q2 25 | 6.1% | 0.4% | ||
| Q1 25 | 6.3% | 0.6% | ||
| Q4 24 | 6.7% | 0.5% | ||
| Q3 24 | 7.2% | 0.6% | ||
| Q2 24 | 3.3% | 0.1% | ||
| Q1 24 | 5.1% | 0.3% |
现金转化率AMPHRPD
| Q4 25 | 1.35× | 12.01× | ||
| Q3 25 | 3.03× | 3.97× | ||
| Q2 25 | 1.15× | 5.70× | ||
| Q1 25 | 1.39× | 14.14× | ||
| Q4 24 | 0.76× | 29.36× | ||
| Q3 24 | 1.48× | 2.85× | ||
| Q2 24 | 1.82× | 5.03× | ||
| Q1 24 | 1.28× | 22.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
RPD
| Products | $209.1M | 96% |
| Services | $8.2M | 4% |
